In the August 8, 2016, Federal Register, FDA announced it is reopening the comment period for the potential development of a user-fee program for nonprescription, or OTC, monograph drugs. FDA initially requested comments and announced a public meeting in the May 11, 2016, Federal Register. The public meeting was held on June 10, 2016, and meeting materials, including a transcript, are available here. FDA recently held a webinar (on September 6, 2016) as a follow-up to the June 2016 public meeting and to provide updates on FDA-industry discussions that began in July 2016 (meeting minutes for those discussions can be found here). Additional information is available here. Comments are due October 6, 2016.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.